Advances in the Treatment of HER2+ Breast Cancer

A panel of expert oncologists review three clinical cases to highlight key clinical trial data and optimal approaches to treating patients with HER2+ breast cancer.

EP. 1: Case 1: Neoadjuvant Therapy for Early-Stage HER2+ BC

May 25th 2022

Centering discussion on a patient case of early-stage HER2+ breast cancer, expert oncologists consider when it is appropriate to utilize neoadjuvant therapy.

EP. 2: Case 1: Neoadjuvant Treatment Armamentarium for Early-Stage HER2+ BC

May 25th 2022

Comprehensive insight on the neoadjuvant treatment armamentarium for early-stage HER2+ breast cancer and the appropriate selection of specific agents.

EP. 3: Case 1: Selecting Adjuvant Therapy for Early-Stage HER2+ BC

June 1st 2022

Shifting their focus to the adjuvant setting, expert panelists review the optimal selection of therapy following surgery in early-stage HER2+ breast cancer.

EP. 4: Case 1: Subcutaneous HP FDC Formulation in Early-Stage HER2+ BC

June 1st 2022

A focused discussion on the subcutaneous formulation of trastuzumab and pertuzumab in patients with early-stage HER2+ breast cancer.

EP. 5: Case 2: Overview of Treatment Strategies for HER2+ Metastatic BC

June 8th 2022

Panelists provide a broad overview of treatment options available for patients diagnosed with HER2+ metastatic breast cancer.

EP. 6: Case 2: DESTINY-Breast03 and T-DXd in HER2+ Metastatic BC

June 8th 2022

Shared insight on the DESTINY-Breast03 trial, which analyzed trastuzumab deruxtecan therapy in patients with HER2+ metastatic breast cancer.

EP. 7: Case 2: Addressing ILD Associated With HER2-Targeted Therapy in mBC

June 15th 2022

Comprehensive discussion on the presence and management of interstitial lung disease in patients being treated for HER2+ metastatic breast cancer.

EP. 8: Case 2: Clinical Experience With Trastuzumab Deruxtecan in HER2+ mBC

June 15th 2022

Expert oncologists share brief notes on their real-world experience managing HER2+ metastatic breast cancer with trastuzumab deruxtecan.

EP. 9: Case 3: Selecting Therapy For HER2+ Breast Cancer With Brain Metastases

June 22nd 2022

Centering discussion on a patient case of HER2+ breast cancer with brain metastases, experts consider optimal treatment regimens in this setting.

EP. 10: Case 2: Third-Line Therapy and Beyond in HER2+ Metastatic Breast Cancer

June 22nd 2022

Focusing on the HER2CLIMB regimen, experts consider appropriate treatment options for patients with HER2+ metastatic breast cancer in the third-line setting and beyond.